CAR T-cell therapy: The future of cancer fight

CAR T-cell therapy, a revolutionary cancer treatment, has moved into the spotlight with actor Sam Neill announcing his remission from stage three cancer after participating in a clinical trial. This innovative therapy involves genetically engineering a patient's own T-cells to enhance their ability to target and destroy cancer cells, a process described as adding a "GPS" to these immune mercenaries.

While CAR T-cell therapies have been approved in Australia since 2018, primarily for blood cancers, research is rapidly advancing. Scientists are now working to adapt these therapies for solid tumors, facing challenges but showing early promise. The treatment offers advantages over traditional chemotherapy, including specificity and speed, though cost remains a significant barrier.

Despite its high cost, the Australian government has announced that Carvykti, a CAR T-cell therapy for multiple myeloma, will be freely available in public hospitals. Experts emphasize the need for continued investment in research and domestic infrastructure to ensure equitable access to these life-saving advancements.